Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive enhancer matrix (GEM) particles
- PMID: 20719246
- DOI: 10.1016/j.ejpb.2010.08.003
Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive enhancer matrix (GEM) particles
Abstract
In this study, a liquid formulation of influenza subunit vaccine admixed with Gram-positive enhancer matrix (GEM) particles as adjuvant was delivered to upper and lower parts of intestinal tract. The aim was to determine the most effective immunization site in the intestines. Mice were vaccinated with a liquid formulation of GEM and influenza subunit vaccine orally and rectally. The oral administration of the vaccine with GEM particles induced a better systemic and mucosal immune response than oral (vaccine only) and rectal (with and without adjuvant) immunizations. Rectal administration elicited high IgG1 responses but little IgG2a, indicating a Th2 dominated immune response. In contrast, the oral immunization with GEM particles elicited a balanced IgG1 and IgG2a response. In conclusion, our results demonstrate that GEM-adjuvanted influenza vaccine should be targeted to the upper part of the intestinal tract.
Copyright © 2010 Elsevier B.V. All rights reserved.
Similar articles
-
Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.Vaccine. 2010 Nov 23;28(50):7963-9. doi: 10.1016/j.vaccine.2010.09.066. Epub 2010 Oct 12. Vaccine. 2010. PMID: 20946860
-
Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice.Vaccine. 2007 Dec 17;25(52):8707-17. doi: 10.1016/j.vaccine.2007.10.035. Epub 2007 Oct 24. Vaccine. 2007. PMID: 17996993
-
A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.Vaccine. 2006 May 1;24(18):3990-4006. doi: 10.1016/j.vaccine.2005.12.017. Epub 2005 Dec 27. Vaccine. 2006. PMID: 16516356
-
Influenza virosomes as a vaccine adjuvant and carrier system.Expert Rev Vaccines. 2011 Apr;10(4):437-46. doi: 10.1586/erv.11.15. Expert Rev Vaccines. 2011. PMID: 21506642 Review.
-
Oral vaccination: where we are?Expert Opin Drug Deliv. 2007 Jul;4(4):323-40. doi: 10.1517/17425247.4.4.323. Expert Opin Drug Deliv. 2007. PMID: 17683247 Review.
Cited by
-
Oral Immunisation With Non-GMO Surface Displayed SARS-CoV-2 Spike Epitopes on Bacteria-Like Particles Provokes Robust Humoral and Cellular Immune Responses, and Modulated the Gut Microbiome in Mice.Microb Biotechnol. 2025 Jan;18(1):e70073. doi: 10.1111/1751-7915.70073. Microb Biotechnol. 2025. PMID: 39797809 Free PMC article.
-
Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications.Front Immunol. 2013 Sep 17;4:282. doi: 10.3389/fimmu.2013.00282. eCollection 2013. Front Immunol. 2013. PMID: 24062748 Free PMC article.
-
The adjuvant effect of bacterium-like particles depends on the route of administration.Front Immunol. 2023 Jan 19;14:1082273. doi: 10.3389/fimmu.2023.1082273. eCollection 2023. Front Immunol. 2023. PMID: 36742329 Free PMC article.
-
Natural peptidoglycan nanoparticles enable rapid antigen purification and potent delivery of plant-derived vaccines.Plant Commun. 2025 Aug 11;6(8):101418. doi: 10.1016/j.xplc.2025.101418. Epub 2025 Jun 16. Plant Commun. 2025. PMID: 40528346 Free PMC article.
-
Activated human nasal epithelial cells modulate specific antibody response against bacterial or viral antigens.PLoS One. 2013;8(2):e55472. doi: 10.1371/journal.pone.0055472. Epub 2013 Feb 6. PLoS One. 2013. PMID: 23405156 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials